How Has the Therapeutic Plasma Exchange Market Evolved Historically and What is its Current Size?
The therapeutic plasma exchange market has seen considerable growth due to a variety of factors.
• The therapeutic plasma exchange market has grown significantly in recent years. It will grow from $1.47 billion in 2024 to $1.62 billion in 2025, at a CAGR of 9.8%.
This growth is driven by the emergence of immunological diseases, technological advancements, greater awareness and education, expanding treatment indications, and a better understanding of disease mechanisms.
What Is The Projected Growth Of The Therapeutic Plasma Exchange Template Market?
The therapeutic plasma exchange market is expected to maintain its strong growth trajectory in upcoming years.
• The therapeutic plasma exchange market is expected to reach $2.32 billion by 2029 with a CAGR of 9.5%.
Factors contributing to growth include the aging population, clinical guidelines, healthcare investments, and reimbursement policies. Key trends include personalized therapies, automation, collaboration, and integration of telemedicine.
What Are The Key Drivers Fueling Growth In The Therapeutic Plasma Exchange Market?
The rise in hematological disorders is anticipated to boost the therapeutic plasma exchange market's growth. Hematological disorders, also referred to as blood disorders, are ailments affecting the blood and tissues that form blood such as lymph nodes, spleen, and bone marrow. The increase in these disorders is attributed to factors like genetic predispositions, environmental impacts, and lifestyle modifications. Therapeutic plasma exchange (TPE) is beneficial in the treatment of hematological disorders as it aids in getting rid of pathogenic substances from the plasma. This includes autoantibodies in autoimmune hemolytic anemia or immune complexes in thrombotic thrombocytopenic purpura, helping to reduce disease severity and enhance patient outcomes. For instance, the Leukemia and Lymphoma Society, a professional organization based in the US, projected an approximate rise of 2.3% in myeloma diagnoses from 2021 to 2023 - increasing from 34,920 to 35,730 in August 2023. Thus, the increasing prevalence of hematological disorders is fuelling the expansion of the therapeutic plasma exchange market.
What Are The Principal Market Segments In The Global Therapeutic Plasma Exchange Industry?
The therapeutic plasma exchange market covered in this report is segmented –
1) By Type: Therapeutic Plasma Exchange (TPE), Double Filtered Plasmapheresis (DFPP)
2) By Indication: Neurological Disorders, Hematological Disorders, Renal Disorders, Metabolic Disorders, Other Indications
3) By Technology: Centrifugation, Membrane Separation
4) By End User: Blood Collection Centers, Hospitals And Clinics, Transfusion Centers, Other End Users
Subsegments:
1) By Therapeutic Plasma Exchange (Tpe): Manual Tpe, Automated Tpe
2) By Double Filtered Plasmapheresis (Dfpp): Single-Stage Dfpp, Multi-Stage Dfpp
Pre-Book The Therapeutic Plasma Exchange Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Therapeutic Plasma Exchange Market?
Many key players in the therapeutic plasma exchange market are pursuing strategic partnerships as a way to augment technology integration and broaden their market presence. A strategic partnership generally implies a mutual alliance between multiple organizations wherein they amalgamate their resources, expertise, and endeavors to accomplish shared goals or objectives. For instance, in July 2022, Terumo Blood and Cell Technologies, an American technology firm, joined forces with Eliaz Therapeutics Inc., - a U.S. medical device firm adept in therapeutic apheresis for inflammatory and kidney-related diseases. They aim to address acute kidney injury (AKI) and Sepsis-induced AKI (S-AKI) through the selective removal of the inflammatory protein Gal-3 from blood plasma. Given the high mortality rates linked to AKI, the partnership intends to investigate new treatments using Terumo's Spectra Optia Apheresis System and ETI's XGal-3 column. Preliminary studies will be conducted on large animals before advancing to human clinical trials. Terumo, recognized for its innovation in therapeutic apheresis, has previously entered collaborative projects targeting diseases like triple-negative breast cancer and COVID-19.
Who Are the Key Players In The Therapeutic Plasma Exchange Market?
Major companies operating in the therapeutic plasma exchange market are:
• Medica S.p.A.
• Fresenius SE and Co. KGaA
• Medtronic Plc.
• Asahi Kasei Corporation
• Toray Industries Inc.
• Baxter International Inc.
• B Braun Melsungen AG
• Terumo Corporation
• Kaneka Corporation
• Charles River Laboratories
• Octapharma AG
• Spectral Medical Inc.
• Nikkiso Co. Ltd.
• Haemonetics Corporation
• Miltenyi Biotec Technology And Trading Co. Ltd.
• Macopharma SA
• Cerus Corporation
• Apellis Pharmaceuticals Inc.
• ImmunoTek Bio Centers LLC
• CytoSorbents Corporation
• Kawasumi Laboratories America Inc.
• Japan Medical Supply Co. Ltd.
What Are The Regional Insights Into The Therapeutic Plasma Exchange Market?
North America was the largest region in the therapeutic plasma exchange market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the therapeutic plasma exchange market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
